ReviewMolecular therapy. Nucleic acids2014
Mir-34: a new weapon against cancer?
Review in Molecular therapy. Nucleic acids, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 307 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
307 citing papers in PubMed, 1 synthesis or guideline pooled it, 498 citations in OpenAlex.
- MicroRNA Expression in Endometrial Cancer: Current Knowledge and Therapeutic Implications.Medicina (Kaunas, Lithuania) · 2024Pooled it
- Antibody-oligonucleotide conjugates: design principles, intracellular delivery, and translational opportunities.Journal of hematology & oncology · 2026Review
- Molecular convergence in gallbladder cancer: MEK-ERK signalling at the crossroads of oncogenic hubs and pathway cross-talks.Cancer cell international · 2026Review
- miRNA-lncRNA Cross-Regulation Landscape in Cancer: From Molecular Mechanisms to Therapeutic and Diagnostic Applications.Cancers · 2026Review
- Nanoparticle-Based miRNA Therapeutics in Breast Cancer Highlighting Design Strategies and Translational Potential.International journal of nanomedicine · 2026Review
- Riding the Wave of Progress: Examining the Current Landscape and Future Potential of MicroRNAs in Cancer Gene Therapy.Current gene therapy · 2026Review
- MicroRNA profiling identifies novel regulators of stem cell function in the adult Drosophila intestine.Scientific reports · 2025Article
- A therapeutic-grade purified exosome system alleviates osteoarthritis by regulating autophagy through the BCL2-Beclin1 axis.Journal of nanobiotechnology · 2025Article
- Molecular Pathways Affected by Sulfonylpurine Derivatives in 2D and 3D HeLa Cell Models.Molecules (Basel, Switzerland) · 2025Article
- Exploring the therapeutic potential of microRNAs: targeted gene regulation strategies for enhanced cancer therapy.Journal, genetic engineering & biotechnology · 2025Review
- Resveratrol-mediated suppression of glioblastoma and glioma: targeting apoptosis, differentiation, and stem cell dynamics.Cancer cell international · 2025Review
- Review
- Dysregulation of MicroRNAs in Hepatocellular Carcinoma: Targeting Oncogenic Signaling Pathways for Innovative Therapies.International journal of molecular sciences · 2025Review
- Article
- Utilizing miR-34a-Loaded HER2-Targeting Exosomes to Improve Breast Cancer Treatment: Insights From an Animal Model.Journal of breast cancer · 2025Article
- Non-coding RNAs in alcohol-associated liver disease.Liver research (Beijing, China) · 2025Review
- Emerging Tumor Biomarkers in Pancreatic Cancer and Their Clinical Implications.Current issues in molecular biology · 2025Review
- Therapeutic Applications of Poly-miRNAs and miRNA Sponges.International journal of molecular sciences · 2025Review
- Suppression of Cellular Proliferation in PC3 Prostate Cancer Cells by Green Tea Extract Through Induction of miR-34a Expression.Food science & nutrition · 2025Article
- The Role of microRNAs in Lung Cancer: Mechanisms, Diagnostics and Therapeutic Potential.International journal of molecular sciences · 2025Review
247 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The microRNA(miRNA)-34a is a key regulator of tumor suppression. It controls the expression of a plethora of target proteins involved in cell cycle, differentiation and apoptosis, and antagonizes processes that are necessary for basic cancer cell viability as well as cancer stemness, metastasis, and chemoresistance. In this review, we focus on the molecular mechanisms of miR-34a-mediated tumor suppression, giving emphasis on the main miR-34a targets, as well as on the principal regulators involved in the modulation of this miRNA. Moreover, we shed light on the miR-34a role in modulating responsiveness to chemotherapy and on the phytonutrients-mediated regulation of miR-34a expression and activity in cancer cells. Given the broad anti-oncogenic activity of miR-34a, we also discuss the substantial benefits of a new therapeutic concept based on nanotechnology delivery of miRNA mimics. In fact, the replacement of oncosuppressor miRNAs provides an effective strategy against tumor heterogeneity and the selective RNA-based delivery systems seems to be an excellent platform for a safe and effective targeting of the tumor.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.